A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

This Phase III study is testing rezvilutamide — an anti-androgen pill (a drug that blocks male hormones that fuel prostate cancer) — combined with standard hormone-lowering therapy (ADT) for men with prostate cancer that has spread but still responds to hormone treatment. **You may be eligible if...** - You are 18 years or older with a confirmed diagnosis of prostate cancer (adenocarcinoma type) - Your cancer has spread to other parts of the body (metastatic) but is still responding to hormone therapy (hormone-sensitive) - You are in good physical condition (ECOG score 0 or 1) - You are planning to receive and maintain hormone-lowering therapy (ADT) throughout the study - Your liver, kidneys, heart, and blood counts are in acceptable range **You may NOT be eligible if...** - Your cancer is neuroendocrine or small cell prostate cancer - You are not hormone-sensitive (castration-resistant) - You are not receiving ADT Talk to your doctor to see if this trial is right for you.